Current update in the management of diabetic nephropathy

Current Diabetes Reviews

Volumn 9, Issue 1, 2013, Pages 62-77

  Van Buren, Peter Noel ^a   Toto, Robert ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Albuminuria; Diabetes; Diabetic nephropathy; Endothelin 1; Hypertension; Renin angiotensin aldosterone system

Indexed keywords

ALISKIREN; AMLODIPINE; ATRESENTAN; AVOSENTAN; BENAZEPRIL; CANDESARTAN; CAPTOPRIL; DOXYCYCLINE; ENALAPRIL; ENDOTHELIN; ENDOTHELIN RECEPTOR ANTAGONIST; GLICLAZIDE; HEMOGLOBIN A1C; INDAPAMIDE PLUS PERINDOPRIL; IRBESARTAN; LISINOPRIL; LOSARTAN; OLMESARTAN; PARICALCITOL; PYRIDORIN; PYRIDOXINE DERIVATIVE; RUBOXISTAURIN; SPIRONOLACTONE; SULODEXIDE; TRANDOLAPRIL; TRANILAST; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSARTAN; VERAPAMIL; VITAMIN D RECEPTOR;

ALBUMINURIA; BLOOD PRESSURE REGULATION; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; COMORBIDITY; DETERIORATION; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC PATIENT; DISEASE COURSE; GENETIC SUSCEPTIBILITY; GLOMERULOSCLEROSIS; GLOMERULUS FILTRATION RATE; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FAILURE; MACROALBUMINURIA; MICROALBUMINURIA; MONOTHERAPY; MORTALITY; NEPHROTIC SYNDROME; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIMARY PREVENTION; PRIORITY JOURNAL; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SECONDARY PREVENTION; ULTRAFILTRATION;

EID: 84875962833     PISSN: 15733998     EISSN: 18756417     Source Type: Journal    
DOI: 10.2174/157339913804143207     Document Type: Review

References (95)

1. Schwartz M, Lewis E, Leonard-Martin T, Lewis J, Batlle DatCSG. Renal pathology patterns in type II diabetes mellitus: relationship with retinopathy. Nephrology Dialysis Transplantation 1998; 13: 2547-2552.
2. Osterby R, Gall M, Schmitz A, Nielsen F, Nyberg G, Parving H. Glomerular structure and function in proteinuric Type 2 (noninsulin-dependent) diabetic patients. Diabetologia 1993; 36: 1064-1070.
3. National Kidney Foundation. KDOQI Clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 2007; 49 (Suppl 2): S1-S180.
4. Mogensen C. Glomerular Filtration Rate and Renal Plasma Flow in Short-term and Long-term Juvenile Diabetes Mellitus. Scandinavian J Clin Lab Invest 1971; 28: 91-100.
5. Magee G, Bilous R, Cardwell C, Hunter S, Kee F, Fogarty D. Is hyperfiltration associated wtih future risk of developing diabetic nephropathy? A meta-analysis. DIabetologia 2009; 52: 691-697.
6. Cherney D, Scholey J, Miller J. Insights into the regulation of renal hemodynamic function in diabetes mellitus. Current Diabetes Reviews 2008; 4: 280-290.
7. Lurbe E, Redon J, Kesani A. Increase in Nocturnal Blood Pressure and Progression to Microalbuminuria in Type 1 Diabetes. New Engl J Med 2002; 347: 797-805.
8. Fagerudd J, Tarnow L, Jacobsen P, et al. Predisposition to essential hypertension and development of diabetic nephropathy in IDDM patients. Diabetes 1998; 47: 439-444.
9. Ismail N, Becker B, Strzelczyk P, Ritz E. Renal disease and hypertension in non-insulin dependent diabetes mellitus. Kidney Int 1999; 55: 1-28.
10. Keller C, Bergis K, Filser D, Ritz E. Renal Findings in Patients with Short Term Type 2 Diabetes. J Am Soc Nephrol 1996; 7: 2627-2635.
11. Perkins B, Ficociello L, Ostrander B. Microalbuminuria and the Risk for Early Progressive Renal Function Decline in Type 1 Diabetes. J Am Soc Nephrol 2007; 18: 1353-1361.
12. Adler KS.RJ, Manley, SE. Development and Progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003; 63: 225-232.
13. Lewis E, Hunsicker L, Clarke W, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860.
14. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869.
15. Packham D, Alves T, Dwyer J, et al. Relative Incidence of ESRD Versus Cardiovascular Mortality in Proteinuric Type 2 Diabetes and Nephropathy: Results from the DIAMETRIC (Diabetes Mellitus Treatment for Renal Insufficiency Consortium) Database. Am J Kidney Dis 2012; 59: 75-83.
16. Monnier V, Vishwanath V, Frank K, Elmets C, Dauchot P, Kohn R. Relation between complications of type 1 diabetes mellitus and collagen-linked fluorescence. New England Journal of Medicine 1986; 314: 403-408.
17. Vlassara H, Striker LJ, Teichberg S, Fuh H, Li YM, Steffes M. Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proceedings of the National Academy of Sciences of the United States of America 1994; 91: 11704-11708.
18. Lassila M, Seah K, Allen T, et al. Accelerated Nephropathy in Diabetic Apolipoprotein E-Knockout Mouse: Role of Advanced Glycation End Products. J Am Soc Nephrol 2004; 15: 2125-2138.
19. Flyvbjerg A, Denner L, Schrijvers BF, et al. Long-term renal effects of a neutralizing RAGE antibody in obese type 2 diabetic mice. Diabetes 2004; 53: 166-172.
20. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005; 54: 1615-1625.
21. Feldt-Rasmussen B, Mathiesen E, Jensen T, Lauritzen T, Deckert T. Effect of improved metabolic control on loss of kidney function in Type 1 (insulin-dependent) diabetic patients: an update of the Steno studies. DIabetologia 1991; 34: 164-170.
22. The Diabetes Control and Complications Trial Research Group. The Effect of Intensive Treatments of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus. New England Journal of Medicine 1993; 329: 977-986.
23. The DCCT/EDIC Research Group. Intensive Diabetes Therapy and Glomerular Filtration Rate in Type 1 Diabetes. New England Journal of Medicine 2011; 365: 2366-2376.
24. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents progression of microvascular complications in Japanes patients with non-insulin dependent diabetes mellitus: a randomized prospective 6 year study. Diabetes Research and Clinical Practice 1995; 28: 103-117.
25. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837-853.
26. The ADVANCE Collaborative Group. Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine 2008; 358: 2560-2572.
27. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of Intenstive Glucose Lowering in Type 2 Diabetes. New England Journal of Medicine 2008; 358: 2545-2559.
28. Ismail-Beigi F, Craven T, Banerji M, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 2010; 376: 419-430.
29. Epstein M, Sowers J. Diabetes mellitus and hypertension. Hypertension 1992; 19: 403-418.
30. Norgaard K, Feldt-Rasmussen B, Johnsen K, et al. Prevalence of hypertension in type 1 (insulin dependent) diabetes mellitus. DIabetologia 1990; 33: 407-410.
31. Van Buren P, Toto R. Hypertension in diabetic nephropathy: epidemiology, mechanisms, and management. Advances in Chronic Kidney Disease 2011; 18: 28-41.
32. Mogensen C. Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. Br Med J 1982; 285: 685-688.
33. Parving H, Andersen A, Smidt U, Svendsen P. Early aggressive anithypertensive treatment reduces rate of decline of kidney function in diabetic nephropathy. Lancet 1983; 321: 1175-1179.
34. Parving H, Andersen A, Smidt U, Hommel E, Mathiesen E, Svendsen P. Effect of antihypertensive treatment on kidney function in diabetic nephropathy. Br Med J 1987; 294: 1443-1447.
35. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. British Medical Journal 1998; 317: 703-713.
36. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329: 1456-1462.
37. Parving HH, Hommel E, Jensen BR, Hansen HP. Long-term beneficial effect of ACE inhibition on diabetic nephropathy in normotensive type 1 diabetic patients. Kidney Int 2001; 60: 228-234.
38. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878.
39. Bilous R, Chaturvedi N, Sjolie A, et al. Effect of Candesartan on Microalbuminuria and Albumin Excretion Rate in Diabetes. Annals of Internal Medicine 2009; 151: 11-20.
40. Mauer M, Zinman B, Gardiner R, et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. New England Journal of Medicine 2009; 361: 40-51.
41. Ruggenenti P, Fassi A, Ilieva A, et al. Preventing Microalbuminuria in Type 2 Diabetes. New Engl J Med 2004; 351: 1941-1951.
42. Haller H, Ito S, Izzo J, et al. Olmesartan for the Delay or Prevention of Microalbuminuria in Type 2 Diabetes. New England Journal of Medicine 2011; 364: 907-917.
43. Lely A, Luik P, Navis G. Angiotensin I-Converting Enzyme: A Pathogenetic Role in Diabetic Renal Damage? Current Diabetes Reviews 2007; 3: 41-52.
44. Rossing K, Jacobsen P, Pietraszek L, Parving H. Renoprotective Effects of Adding Angiotensin II Receptor Blocker to Maximal Recommended Doses of ACE Inhibitor in Diabetic Nephropathy. Diabetes Care 2003; 26: 2268-2274.
45. Jacobsen P, Andersen S, Jensen B, Parving H. Additive Effect of ACE Inhibition and Angiotensin II Receptor Blockade in Type 1 Diabetic Patients with Diabetic Nephropathy. J Am Soc Nephrol 2003; 14: 992-999.
46. Andersen N, Poulsen P, Knudson S, et al. Long-Term Dual Blockade With Candesartan and Lisinopril in Hypertensive Patients With Diabetes. Diabetes Care 2005; 28: 273-277.
47. Yusuf S, Teo K, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Andersen C. Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events. New England Journal of Medicine 2008; 358: 1547-1559.
48. Mann J, Schmieder R, McQueen M, Dyal L, et al. Renal outcomes with telmisartan, ramipril, or both in people at high vascular risk (the ONTARGET study): a multicentre, randomized, double-blind, controlled trial. Lancet 2008; 372: 547-553.
49. Imai E, Chan J, Ito S. Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo controlled study. DIabetologia 2011; 54: 2978-2986.
50. Department of Veteran Affairs; Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy; VA NEPHRON-D Study: Nephropathy iN Diabetes Study. In: Clinical Trials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-[cited 2012 March 26]. Available from http://www.clinicaltrials.gov/ct2/show/NCT00555217NLMIdentifierNCT00555217.
51. Sato A, Hayashi K, Naruse M, Saruta T. Effectiveness of Aldosterone Blockade in Patients with Diabetic Nephropathy. Hypertension 2003; 41: 64-68.
52. Schjoedt K, Andersen S, Rossing P, Tarnow L, Parving H. Aldosterone escape during blockade of the renin angiotensinaldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate. Diabetologia 2004; 47: 1936-1939.
53. Schjoedt K, Rossing K, Juhl T, et al. Beneficial impact of spironolactone in diabetic nephropathy. Kidney International 2005; 68: 2829-2836.
54. Schjoedt KJ, Rossing K, Juhl TR, Boomsma F, Tarnow L, Rossing P, Parving HH. Beneficial impact of spironolactone on nephritic range albuminuria in diabetic nephropathy. Kidney Int 2006; 70: 536-542.
55. Mehdi U, Adams-Huet B, Raskin P, Vega G, Toto R. Addition of Angiotensin Receptor Blockade or a Mineralocorticoid Antagonism to Maximal Angiotensin-Converting Enzyme Inhibition in Diabetic Nephropathy. Journal of the American Society of Nephrology 2009; 20: 2641-2650.
56. Khosla N, Kalaitzidis R, Bakris G. Predictors of Hyperkalemia Risk following Hypertension Control with Aldosterone Blockade. Am J Nephrol 2009; 30: 418-424.
57. Persson F, Rossing P, Schjoedt K, et al. Time course of the antiproteinuric and anithypertensive effects of the direct rennin inhibition in type 2 diabetes. Kidney Int 2008; 73: 1419-1425.
58. Parving H, Persson F, Lewis J, Lewis E, Hollenberg N. Aliskiren combined with losartan in type 2 diabetes and nephropathy. New Engl J Med 2008; 358: 2433-2446.
59. Persson F, Rossing P, Reinhard H. Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria. Diabetes Care 2009; 32: 1873-1879.
60. Parving H, Brenner B, McMurray J, et al. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant 2009; 24: 1663-1671.
61. Aliskiren-containing Medications: Drug Safety Communication- New Warning and Contraindication. Posted April 20, 2012. Accessed May 4, 2012. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm301120.htm?source=govdelivery, 2012.
62. Zheng F, Zeng Y-J, Plati A, et al. Combined AGE inhibition and ACEi decreases the progression of established diabetic nephropathy in B6 db/db mice. Kidney International 2006; 70: 507-514.
63. Williams M, Bolton W, Khalifah R, Degenhardt T, Schotzinger R, McGill J. Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. Am J Nephrology 2007; 27: 605-614.
64. Lewis EJ, Greene T, Spitalewiz S, et al. Pyridorin in type 2 diabetic nephropathy. J Am Soc Nephrol 2012; 23: 131-136.
65. Tuttle KR, Bakris GL, Toto RD, McGill JB, Hu K, Anderson PW. The effect of ruboxistaurin on nephropathy in type 2 diabetes. Diabetes Care 2005; 28: 2686-2690.
66. Tuttle KR, McGill JB, Haney DJ, Lin TE, Anderson PW. Kidney outcomes in long-term studies of ruboxistaurin for diabetic eye disease. Clin J am Soc Nephrol 2007; 2: 631-636.
67. Menne J, Meier M, Park J, Haller H. Inhibition of protein kinase C in diabetic nephropathy-where do we stand? Nephrol Dial Transplant 2009; 24: 2021-2023.
68. RamachandraRao SP, Zhu Y, Ravasi T, et al. Pirfenidone is renoprotective in diabetic kidney disease. J Am Soc Nephrol 2009; 20: 1765-1775.
69. Sharma K, Ix JH, Mathew AV, et al. Pirfenidone for diabetic nephropathy. J Am Soc Nephrol 2011; 22: 1144-1151.
70. Mifsud S, Kelly DJ, Qi W, Zhang Y, Pollock CA, Wilkinson-Berka JL, Gilbert RE. Intervention with tranilast attenuates renal pathology and albuminuria in advanced experimental diabetic nephropathy. Nephron Physiology 2003; 95: p83-91.
71. Akahori H, Ota T, Torita M, Ando H, Kaneko S, Takamura T. Tranilast prevents the progression of experimental diabetic nephropathy through suppression of enhanced extracellular matrix gene expression. The Journal of pharmacology and experimental therapeutics 2005; 314: 514-521.
72. Soma J, Sato K, Saito H, Tsuchiya Y. Effect of Tranilast in Early-Stage Diabetic Nephropathy. Nephrol Dial Transplant 2006; 21: 2795-2799.
73. Gambaro G, Kinalsaka I, Oksa A, et al. Oral Sulodexide Reduces Albuminuria in Microalbuminuric and Macroalbuminuric Type 1 and Type 2 Diabetic Patients: The DINAS Randomized Trial. J Am Soc Nephrol 2002; 13: 1615-1625.
74. Aggarwal HK, Jain D, Talapatra P, Yadav RK, Gupta T, Kathuria KL. Evaluation of role of doxycycline (a matrix metalloproteinase inhibitor) on renal functions in patients of diabetic nephropathy. Renal failure 2010; 32: 941-946.
75. Naini AE, Harandi AA, Moghtaderi J, Bastani B, Amiran A. Doxycycline: a pilot study to reduce diabetic proteinuria. American journal of nephrology 2007; 27: 269-273.
76. Packham DK, Wolfe R, Reutens AT, et al. Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy. Journal of the American Society of Nephrology: JASN 2012; 23: 123-130.
77. Kakizawa H, Itoh M, Itoh Y, et al. The Relationship Between Glycemic Control and Plasma Vascular Endothelial Growth Factor and Endothelin-1 Concentration in Diabetic Patients. Metabolism 2004; 53: 550-556.
78. Minchenko A, Stevens M, White L, et al. Diabetes-induced overexpression of endothelin-1 and endothelin receptors in the rat renal cortex is mediated via poly (ADP-ribose) polymerase activation. FASEB 2003; 17: 1514-1516.
79. Wenzel R, Littke T, Kuranoff S, et al. Avosentan Reduces Albumin Excretion in Diabetics with Macroalbuminuria. J Am Soc Nephrol 2009; 20: 655-664.
80. Mann J, Green D, Jamerson K, et al. Avosentan for Overt Diabetic Nephropathy. J Am Soc Nephrol 2010; 21: 527-535.
81. Kohan D, Pritchett Y, Molitch M, et al. Addition of Atrasentan to Renin-Angiotensin System Blockade Reduces Albuminuria in Diabetic Nephropathy. J Am Soc Nephrol 2011; 22: 763-772.
82. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414: 813-820.
83. Chabrashvili T, Kitiyakara C, Blau J, et al. Effects of Ang II Type 1 and 2 receptors on oxidative stress, renal NADPH oxidase, and SOD expression. Am J Physiol Regul Integr Compl Physiol 2003; 285: R117-R124.
84. Kim H, Vaziri N. Contribution of impaired Nrf2-Keap1 pathway to oxidative stress and inflammation in chronic renal failure. Am J Physiol Renal Physiol 2010; 298: F662-F671.
85. Yoh K, Hirayama AI.K, Yamada A, et al. Hyperglycemia induces oxidative and nitrosative stress and increases renal functional impairment in Nrf2-deficient mice. Genes to Cells 2008; 13: 1159-1170.
86. Pergola P, Krauth M, Huff J, et al. Effect of Bardoxolone Methyl on Kidney Function in Patients with T2D and Stage 3b-4 CKD. Am J Nephrology 2011; 33: 469-476.
87. Pergola P, Raskin P, Toto R, Meyer C, Huff J, et al.Grossman E, Krauth M, Ruiz S, Audhya P, Christ-Schmidt H, Wittes J, Warnock D, Investigators BS. Bardoxolone Methyl and Kidney Function in CKD with Type 2 Diabetes. New England Journal of Medicine 2011; 365: 327-336.
88. Reata Pharmaceuticals I: Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes (BEACON). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000[cited February 29, 2012] Available from http://www.clinicaltrials.gov/ct2/show/NCT01351675NLMIdentifier01351675.
89. Ishikawa Y, Gohda T, Tanimoto M, et al. Effect of Exercise on Kidney Function, Oxidative Stress, and Inflammation in Type 2 Diabetic kk-a(y) Mice. Experimental Diabetes Research 2012; 2012. (in press).
90. Li Y, Kong J, Wei M, Chen Z, Liu S, Cao L. 1,25-Dihydroxyvitamin D3 is a negative endocrine regulator of the renin-angiotensin system. Journal of Clinical Investigation 2002; 110: 229-238.
91. Zhou C, Lu F, Cao K, Goltzman D, Miao D. Calcium-independent and 1,25(OH)2D3-dependent regulation of the renin-angiotensin system in 1 alpha-hydroxylase knockout mice. Kidney Int 2008; 74: 170-179.
92. Zhang Z, Sun L, Wang Y, et al. Renoprotective role of the vitamin D receptor in diabetic nephropathy. Kidney Int 2008; 73: 163-171.
93. Li Y. Podocytes as Target of Vitamin D. Current diabetes reviews 2011; 7: 35-40.
94. de Zeeuw D, Agarwal R, Amdahl M, Audhya P, Coyne DG.T, Parving H, Pritchett Y, Remuzzi G, Ritz E, Andress D. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. The Lancet 2010; 376: 1543-1551.
95. Lambers Heerspink H, Holtkamp F, Parving H, et al. Moderation of dietary sodium potentiates the renal and cardiovascular protective effects of angiotensin receptor blockers. Kidney Int 2012; 82: 330-337.